Baili Tianheng announced that BL-M09D1, an innovative biopharmaceutical independently developed by the company, has obtained the “Drug Clinical Trial Approval Notice” officially approved and issued by the State Drug Administration, agreeing to conduct clinical trials in patients with advanced solid tumors. BL-M09D1 is an ADC drug that comes from the same small molecule technology platform and shares the same “connector+toxin” platform as BL-B01D1. It is indicated for advanced solid tumors.

Baili Tianheng announced that BL-M09D1, an innovative biopharmaceutical independently developed by the company, has obtained the “Drug Clinical Trial Approval Notice” officially approved and issued by the State Drug Administration, agreeing to conduct clinical trials in patients with advanced solid tumors. BL-M09D1 is an ADC drug that comes from the same small molecule technology platform and shares the same “connector+toxin” platform as BL-B01D1. It is indicated for advanced solid tumors.